24
Aug
Aug
The published thymosin beta-4 study figures, the animal numbers, and the honest answer for TB-500 itself: no human dose has ever been published.
23
Aug
Aug
What amounts has BPC-157 research actually used? The published animal figures, the human-tissue concentrations, and the honest answer on human dosing: none is published.
23
Aug
Aug
BPC-157 is studied in animal, cell, and tissue models of tendon, gut, blood vessel, nerve, and wound repair. A plain-language map of every research area.
23
Aug
Aug
BPC-157 is on the WADA Prohibited List in Section S2, prohibited at all times for tested athletes. What that means, and why the source is no defense.
23
Aug
Aug
BPC-157 and KPV are studied for different things, and both appear in gut research. A plain-language look at what the published work covers and what it does not.
23
Aug
Aug
A plain-language comparison of BPC-157 and GHK-Cu: structure, size, the pathways each is studied through, the research areas each belongs to, and what neither has been tested for in people.
23
Aug
Aug
What the published record actually reports about BPC-157 safety: no Phase II or III human efficacy trial, small pilot infusion references, and open questions.
23
Aug
Aug
BPC-157 is not an FDA-approved drug. What that means, the 2023-2026 compounding timeline, and how “approved,” “scheduled,” and “compounding list” differ.
23
Aug
Aug
A plain answer to a question most sellers avoid: no Phase II or III human trial of BPC-157 has ever been published. Here is what the human record actually holds.
23
Aug
Aug
How standalone BPC-157 differs from the pre-mixed blends that contain it, what is in each vial, and why combining peptides is a research idea, not a proven bigger effect.